Pharmacology

Evexta Bio

Heidi Rohwer, 5 March, 2026, 0

First-in-class clinical stage dual PAM inhibitor overcoming endocrine resistance in breast cancer

Flavii Therapeutics

Heidi Rohwer, 18 December, 2025, 0

Unlocking new therapeutic avenues for CNS disorders through G9a Inhibition

MB Therapeutics

Heidi Rohwer, 15 December, 2025, 0

Automatic production of personalized oral forms

DETERA Therapeutics

Heidi Rohwer, 3 November, 2025, 0

Developing disruptive therapies for rare kidney diseases

RonomA

Lilly Moran, 29 January, 2025, 0

Developing a new therapeutic approach to change the course of Alzheimer disease

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR

Aviso de cookies

Pharmacology

Evexta Bio

Flavii Therapeutics

MB Therapeutics

DETERA Therapeutics

RonomA

Capital Cell Barcelona

Links

About cookies

Pharmacology

Evexta Bio

Flavii Therapeutics

MB Therapeutics

DETERA Therapeutics

RonomA

Capital Cell Barcelona

Links

About cookies

Log in with your credentials

Forgot your details?

Create Account